The company's Owkin Socrates platform applies transfer and federated learning to clinical research.
The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
The agreement tasks Adimab with turning its yeast-based antibody discovery platform against multiple targets picked out by Boehringer.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
Datavant will partner its 150 data sets with the three organizations' unique capabilities to drive clinical trial intelligence.
BioNTech will work with Scancell to discover and characterize T cell receptors and has an option to form a license agreement for the therapeutics.
The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and sees Sanofi obtain worldwide rights to fitusiran.
The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.